Manufacturer
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Contents
Lansoprazole
Indication
Gastric, duodenal & stomal ulcer, reflux esophagitis. Relief of reflux-like symptoms eg, heartburn &/or ulcer-like symptoms eg, upper epigastric pain associated w/ acid-related dyspepsia. Treatment & prophylaxis of NSAID-associated benign gastric & duodenal ulcers & symptomatic relief in patients requiring continued NSAID treatment. Zollinger-Ellison syndrome, H pylori eradication. Symptomatic GERD & erosive esophagitis in childn 12-17 yr.
Instruction
Should be taken on an empty stomach: Place tab on the tongue & allow it to disintegrate, w/ or w/o water. Do not chew. Tab may also be administered via an oral syringe or a nasogastric tube ≥8 French. For oral syringe or nasogastric tube administration, place 30 mg tab in a syringe & draw up 10 mL of water. Shake syringe to disperse the tab & administer w/in 15 min. Refill syringe w/ 5 mL of water, shake gently & administer any remaining contents.
Drug interaction
Increased INR & prothrombin time w/ warfarin. Delayed absorption & reduced biovailability w/ sucralfate. Interfered absorption of ketoconazole, ampicillin esters, Fe salts, digoxin. Reduced bioavailability of HIV PIs eg, atazanavir, nelfinavir. Elevated & prolonged serum levels of methotrexate &/or its metabolite. Increased whole blood levels of tacrolimus. Increased systemic exposure w/ fluvoxamine.
Malaysia
